Using the drop-down menu below, read about highlighted scientific news for patients from ASCO's Annual Meetings, Symposia, and medical journals for the past three years. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
This includes ASCO’s Journal of Clinical Oncology and its scientific meetings, including the ASCO Annual Meeting, a five-day meeting held each May/June. To read the Annual Meeting summaries compiled into a yearly newsletter, you can also review Research Round Up: News for Patients from the ASCO Annual Meeting. Don’t forget to check out audio podcasts and videos about this news, as well. And a list of upcoming Symposia can be found here. And, in addition to the highlighted studies below, thousands of scientific abstracts are released each year at different ASCO meetings. To search the entire collection of meeting abstracts, visit ASCO's website.
A new study provides clarification on the best time for patients to receive lymph node surgery for early-stage oral cancer.
Recently, researchers found that nivolumab (Opdivo) either given as a single treatment or in combination with ipilimumab (Yervoy) is more effective than treatment with ipilimumab alone for people with advanced melanoma.
A recent analysis of information from more than 34,000 children who participated in the Childhood Cancer Survivor Study shows that modern cancer care is reducing deaths from cancer and long-term side effects.
In a recent study, researchers found that radiation therapy to the whole brain after radiosurgery for cancer that has spread to the brain causes more thought and memory problems than just radiosurgery. Even though the additional radiation therapy controlled the cancer’s growth, it did not lengthen patients’ lives.
A large clinical trial suggests that anastrazole (Arimidex) may be a new option for preventing breast cancer after treatment for ductal carcinoma in situ (DCIS). DCIS is a non-invasive type of breast cancer. DCIS can usually be eliminated with a lumpectomy followed by radiation therapy. However, women with DCIS are at increased risk for developing invasive breast cancer in the same or opposite breast.
A recent study showed that the drug pacritinib works better for myelofibrosis than current treatments.
A large phase III study has found that a new targeted therapy, called palbociclib (Ibrance), delayed the growth and spread of advanced hormone receptor-positive breast cancer by roughly five months when combined with the standard hormonal therapy fulvestrant (Faslodex). This combination could become a new treatment option for women with hormone receptor-positive, HER2-negative breast cancer that has spread to other parts of the body.
In an ongoing study, researchers found that adding a new targeted therapy to chemotherapy controls non-Hodgkin lymphoma (NHL) growth for more than twice as long as only chemotherapy.
According to a recent small study, the drug daratumumab may work well as a treatment for multiple myeloma after other treatments have not worked.
A recent study shows that adding docetaxel (Docefrez, Taxotere) chemotherapy to the standard treatment of hormone therapy and radiation therapy helps men with high-risk, localized prostate cancer live longer.